ERBB2 and ductal breast carcinoma in situ: To validate the findings from the spatial transcriptomic analyses in a larger dataset and to compare the profiles of HER2-positive tumors with those of HER2-negative tumors, we explored a previously published gene expression dataset derived from bulk tissue samples, including DCIS and invasive tumors, across all subtypes [16].